Shares of pharmaceutical companies are on a roll trading higher by up to 10% in late noon deals on the Bombay Stock Exchange (BSE).
Ranbaxy Laboratories, Ipca Laboratories, Lupin, Aurobindo Pharma, Dr Reddy’s Laboratories and Cipla are up in the range on 3-10%. The BSE healthcare index is up 1.8% as compared to 1.3% rise in benchmark S&P BSE Sensex at 1425 hours.
Ranbaxy Laboratories has rallied 10% to Rs 447 on buzz that the drug maker may get US Food and Drugs Administration (USFDA) nod to launch the generic version of Novartis' anti-hypertension blockbuster Diovan in the US market this quarter.
Shares of pharmaceutical firm has zoomed 76% from low of Rs 254 touched on August 2 on BSE.
The drug, which went off-patent in September 2012, enjoys sales of over $2 billion in the US market and is expected to generate $187 million for Ranbaxy during its six-month exclusivity period, the Bloomberg report suggests.
Ipca Laboratories has soared nearly 8% at Rs 697 after the company said US-FDA has found acceptable the company's oral solid dosage formulations manufacturing facility situated at Pharmazone, SEZ Indore, Pithampur, Madhya Pradesh.
This will enable the company to commercialize oral solid dosage formulations in the US market from this formulations manufacturing facility, Ipca Lab said in a regulatory filing.
Aurobindo Pharma and Lupin are up 4% each, while Biocon, Dr Reddy’s Laboratories and Cipla gained 3% each on BSE.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.